At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,469 enrolled
Drug / intervention
adalimumabdrug
Likely dose
40 mg subcutaneously every other week or 40 mg every weekAI-extracted
Key inclusion· 3
- ✓Age 18 years or older
- ✓In good health with recent stable medical history (per investigator judgment)
- ✓Completed prior adalimumab psoriasis clinical study
Key exclusion· 2
- ✕Pregnant or breast-feeding or planning pregnancy
- ✕Deemed unsuitable for study by investigator for any reason
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab
In Brief
A Phase 3 clinical trial evaluating adalimumab for Psoriasis. Completed, enrolled 1,469 participants across 104 sites in 10 countries.
Detailed Summary
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustria, Belgium, Canada, France, Germany, Poland, Puerto Rico, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2004
First PostedSep 2005
Primary CompletionOct 2009
TodayJul 2026
First PostedSep 20, 2005
Enrollment StartMay 1, 2004
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 20.8 years ago
Interventions
adalimumabdrug
40 mg every other week or 40 mg every week by subcutaneous injection